Skip to content

Multidisciplinary Rehabilitation Registration Study on Parkinson's disease (MRPD)

Chinese Parkinson's disease and Parkinson's syndrome multidisciplinary rehabilitation registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033768
Enrollment
Unknown
Registered
2020-06-11
Start date
2020-06-11
Completion date
Unknown
Last updated
2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease/Parkinson syndrome

Interventions

experimental group:Multidisciplinary intensive rehabilitation therapy+Remote motion management
control group:Remote Multidisciplinary rehabilitation therapy

Sponsors

Beijing Rehabilitation Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Aged >= 30 years,<= 75 years; No restrictions on men or women; 2) According to the diagnostic criteria of MDS primary Parkinson's disease, the diagnosis is clinically confirmed Parkinson's disease or clinically probable Parkinson's disease;or diagnosis is parkinson syndrome. 3) The H-Y 1-4; 4) Patients who take anti-Parkinson drugs for more than one month with stable symptoms and do not need drug adjustment in the short term; 5) The patient agrees to conduct the study and signs the informed consent.

Exclusion criteria

Exclusion criteria: 1) Those using beta blockers; 2) Users of anti-psychotropic drugs; 3) With heart disease, (including but not limited to, unstable angina, myocardial infarction, arrhythmia, uncontrolled high blood pressure), respiratory disease, (including but not limited to, COPD, asthma, emphysema, etc.), nervous system diseases (including but not limited to, cerebrovascular diseases, etc.), bone (including but not limited to, joint replacement surgery, severe osteoporosis, etc.), such as serious complications, are contraindications to rehabilitation training; 4) Severe visual, hearing, or cognitive impairment (MMSE & LT < 24 points), unable to cooperate with the assessment task; 5) Patients with uncontrolled epilepsy, central nervous system disease, mental disorder or malignant tumor history, whose clinical severity is judged by the researcher to affect the compliance of the clinical study; 6) Unable to use the Smart phone or Internet.

Design outcomes

Primary

MeasureTime frame
PQD-39;

Secondary

MeasureTime frame
MDS-UPDRS;Levodopa Equivalent dose;Healthcare burden (Healthcare costs);

Countries

China

Contacts

Public ContactBoyan Fang

Beijing Rehabilitation Hospital, Capital Medical University

fangboyanv@ccmu.edu.cn+86 18801086480

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026